🧬 Risk, Recurrence, Relief: Apixaban's Edge in VTE 🌡️ Emphasizes the risk stratification, recurrence data, and therapeutic benefit
Dr RR Baliga's "Got Knowledge Doc" Podkast
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
🩺 New Insights on Apixaban for VTE!
📢 The HI-PRO trial challenges the old 3-month rule for provoked VTE.
📉 Extended low-dose apixaban (2.5 mg BID) reduced recurrent VTE from 10.0% ➡️ 1.3% with minimal major bleeding.
🎯 Editorial in NEJM urges a shift from binary labels ("provoked vs unprovoked") to a patient-centered, risk-adapted approach.
🧠 Art meets evidence in the decision to extend anticoagulation.
💬 Let's rethink how we label, risk-stratify, and treat.
📚 #VTE #Apixaban #Anticoagulation #NEJM #HI_PRO #Thrombosis #PrecisionMedicine #SharedDecisionMaking #EvidenceBasedMedicine #Cardiology